Sanofi

Organisation

46, avenue de la Grande ArmEe, Paris, France, 75017

Headquarters

74846

Employees

Health Technology

Industry

Paul Hudson

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. Sanofi has a strategic collaboration with miRecule, Inc. to facilitate the advancement of therapy DUX4, a genetic driver of debilitating muscular disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Price

Target

Sanofi (SNY) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Sanofi (SNY) share price will touch around $57.34 in next 12-months.

Currently 31 wall-street analysts regularly analyze the financials of Sanofi on a frequent basis to provide recommendations along with target share price. 31 analysts offering 12-month price forecasts for Sanofi (SNY) have a share price target of $57.34. This median of share price forecast represents a 22.22% upside from the latest price of $46.92 as on 08.04.26.

Sanofi (SNY) Share Price Forecast

Home

US Stocks

Sanofi (SNY)

Sanofi Stock Forecast

Sanofi Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Sanofi (SNY): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Sanofi's share price and its median forecast price. As on 08.04.26, the difference is -16.77%

Sanofi Forecast and Target Price

Sanofi (SNY) Share Price Forecast

Sanofi (SNY) Price vs Consensus Price Target

Sanofi (SNY) Share Price Forecast v/s Share Price Today

Sanofi (SNY): Difference between Current Price & Median Forecasted Price

Sanofi (SNY) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price